Clinical timing and benefit of antiviral treatment for hepatitis C
10.3760/cma.j.issn.1007-3418.2017.03.002
- VernacularTitle: 丙型肝炎抗病毒治疗的时机与获益
- Author:
Lichang CHEN
1
;
Qing XIE
Author Information
1. Department of Infectious Diseases, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
- Publication Type:Journal Article
- Keywords:
Hepatitis C;
Virus infection;
Therapeutic starting point;
Clinical benefit;
Interferon, pegylated;
Direct antiviral agents
- From:
Chinese Journal of Hepatology
2017;25(3):164-169
- CountryChina
- Language:Chinese
-
Abstract:
Current treatments for hepatitis C include pegylated interferon-α (Peg-IFNα) and ribavirin (RBV) combination therapy and direct antiviral agents (DAAs). Antiviral treatment can be initiated after 4 to 6 months of clinical observations for patients with acute infections, but should be started as early as possible for those with chronic infections. However, for patients who are ineligible for Peg-IFN and RBV combination therapy and have no unrestricted access to DAAs, it is advised that they wait for the approval of DAAs in China if their medical condition is under control. Though, antiviral therapy should be started immediately if the disease progresses. It has been reported that there are numerous clinical benefits of antiviral treatment for hepatitis C. However, the long-term impact of DAAs treatment including efficacy and safety is limited and remains to be explored.
